{
    "2021-03-23": [
        [
            {
                "time": "2023-03-15",
                "original_text": "UPDATE 1-Novartis says radioligand therapy improves prostate cancer survival",
                "features": {
                    "keywords": [
                        "radioligand therapy",
                        "prostate cancer",
                        "survival",
                        "Novartis"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-03-15",
                "original_text": "Novartis' Radioligand Therapy Hits Primary Endpoint Goal In Prostate Cancer Study",
                "features": {
                    "keywords": [
                        "Radioligand Therapy",
                        "Primary Endpoint",
                        "Prostate Cancer",
                        "Study"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-03-15",
                "original_text": "Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer",
                "features": {
                    "keywords": [
                        "Novartis",
                        "positive result",
                        "phase III",
                        "radioligand therapy",
                        "advanced prostate cancer"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}